DK2714740T3 - Neutraliserende prolactinreceptor-antistof mat3 og terapeutisk anvendelse deraf - Google Patents
Neutraliserende prolactinreceptor-antistof mat3 og terapeutisk anvendelse deraf Download PDFInfo
- Publication number
- DK2714740T3 DK2714740T3 DK12729030.2T DK12729030T DK2714740T3 DK 2714740 T3 DK2714740 T3 DK 2714740T3 DK 12729030 T DK12729030 T DK 12729030T DK 2714740 T3 DK2714740 T3 DK 2714740T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- antigen
- host cell
- acid sequence
- binding fragment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (22)
1. Antistof Mat3 eller antigenbindende fragmenter deraf, som antagoniserer prolactinreceptor-medieret signallering, hvor antistoffet eller de antigenbindende fragmenter deraf omfatter a. en variabel tung region med en aminosyresekvens ifølge SEQ ID NO: 1 og b. en variabel let region med en aminosyresekvens ifølge SEQ ID NO: 2.
2. Antistof eller antigenbindende fragmenter deraf ifølge krav 1, hvor antistoffet eller de antigenbindende fragmenter deraf består af en antigenbindende region, der binder specifikt til en eller flere regioner af det ekstracellulære domæne af prolactinreceptor (PRLR) fra menneske, abe og mus, og hvor aminosyresekvensen for den humane PRLR er vist ved aminosyresekvensen fra position 1 til 210 af SEQ ID NO: 12 og humane polymorfe varianter af SEQ ID NO: 12, ved aminosyresekvensen fra position 1 til 210 af abe-PRLR'en ifølge SEQ ID NO: 11 og af muse-PRLR'en ifølge SEQ ID NO: 13.
3. Antistof eller antigenbindende fragmenter deraf ifølge krav 2, hvor affiniteten til det ekstracellulære domæne af PRLR fra menneske, abe og mus er 100 nM, mindre end 30 nM, eller en affinitet på 10 nM, og hvor affiniteten er blevet målt ved hjælp af overflade-plasmonresonans, for eksempel Biacore.
4. Antistof eller antigenbindende fragmenter deraf ifølge krav 1, hvor antistoffet består af en antigenbindende region, der binder specifikt til en eller flere regioner af det ekstracellulære domæne af human PRLR, og hvor affiniteten er 10 nM eller 1 nM, og hvor affiniteten er blevet målt ved hjælp af overflade-plasmonresonans, for eksempel Biacore.
5. Antistof eller antigenbindende fragmenter deraf ifølge et hvilket som helst af kravene 1 til 4, hvor de konstante domæner af tung kæde er modificeret eller umodificeret IgGl, IgG2, IgG3 eller IgG4.
6. Isoleret nukleinsyresekvens, der koder for et antistof eller et antigenbindende fragment ifølge et hvilket som helst af kravene 1 til 5.
7. Isoleret nukleinsyresekvens ifølge krav 6, hvor den isolerede nukleinsyresekvenser er ifølge SEQ ID NO: 3 og 4.
8. Ekspressionvektor, der omfatter en nukleinsyresekvens ifølge krav 6 eller 7.
9. Værtscelle, der omfatter vektoren ifølge krav 8 eller et nukleinsyremolekyle ifølge krav 6 eller 7, hvor værtscellen er en højere eukaryot værtscelle, en lavere eukaryot værtscelle eller en prokaryot celle.
10. Værtscelle ifølge krav 9, hvor den højere eukaryote værtscelle er en mammaliacelle.
11. Værtscelle ifølge krav 9, hvor den lavere eukaryote værtscelle er en gærcelle.
12. Værtscelle ifølge krav 9, hvor den prokaryote celle er en bakteriecelle.
13. Fremgangsmåde til anvendelse af værtscellen ifølge et hvilket som helst af kravene 9 til 12 til frembringelse af et antistof eller et antigenbindende fragment, som omfatter dyrkning af værtscellen ifølge krav 9 under egnede betingelser og indvinding af antistoffet.
14. Antistof eller antigenbindende fragment, der er frembragt ved hjælp af fremgangsmåden ifølge krav 13.
15. Antistof eller antigenbindende fragment ifølge et hvilket som helst af kravene 1 til 5, der er oprenset til mindst 95 vægt-% homogenitet.
16. Antistof eller antigenbindende fragment ifølge et hvilket som helst af kravene 1 til 5 til anvendelse som et medikament.
17. Farmaceutisk sammensætning, der omfatter antistoffet eller det antigenbindende fragment ifølge et hvilket som helst af kravene 1 til 5 og et farmaceutisk acceptabelt bæremateriale, der omfatter excipienser og hjælpestoffer.
18. Kit, der omfatter et antistof ifølge krav 1 til 5, der omfatter en terapeutisk effektiv mængde af antistof Mat3, der er pakket i en beholder, hvilket kit eventuelt indeholder et andet terapeutisk middel, og yderligere omfatter en etiket, der er fastgjort til eller pakket med beholderen, hvilken etiket beskriver indholdet i beholderen og tilvejebringer indikationer og/eller anvisninger med hensyn til anvendelsen af indholdet i beholderen til behandling af endometriose, adenomyose, benign brystsygdom og mastalgi, laktationshæmning, hårtab som følge af hyper- og normoprolaktinemi, benign prostatahyperplasi, fibroider eller til anvendelse som ikke-hormonelt præventionsmiddel til kvinder eller til behandling af kvinder, der er i kombineret hormonterapi, østrogen plus progestin-terapi, til hæmning af brystepitelcelleproliferation eller til behandling og forebyggelse af antiøstrogenresistent brystcancer.
19. Antistof eller antigenbindende fragment ifølge et hvilket som helst af kravene 1 til 5 til anvendelse i et medikament til behandling og/eller forebyggelse af endometriose og adenomyose, endometriosis interna.
20. Antistof eller antigenbindende fragment ifølge et hvilket som helst af kravene 1 til 5 til anvendelse i et medikament til behandling of benign brystsygdom og mastalgi.
21. Antistof eller antigenbindende fragment ifølge et hvilket som helst af kravene 1 til 5 til anvendelse i et medikament til behandling eller forebyggelse af antiøstrogenresistent brystcancer .
22. Farmaceutisk sammensætning ifølge krav 17, der omfatter et PRLR-antistoffer eller antigenbindende fragmenter ifølge et hvilket som helst af kravene 1 til 5 i kombination med mindst ét andet middel.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11168644A EP2530089A1 (en) | 2011-06-03 | 2011-06-03 | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| PCT/EP2012/060078 WO2012163932A1 (en) | 2011-06-03 | 2012-05-31 | Neutralizing prolactin receptor antibody mat3 and its therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2714740T3 true DK2714740T3 (da) | 2016-05-30 |
Family
ID=46331236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12729030.2T DK2714740T3 (da) | 2011-06-03 | 2012-05-31 | Neutraliserende prolactinreceptor-antistof mat3 og terapeutisk anvendelse deraf |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US9353186B2 (da) |
| EP (2) | EP2530089A1 (da) |
| JP (1) | JP5859641B2 (da) |
| KR (1) | KR101920521B1 (da) |
| CN (1) | CN103764679B (da) |
| AP (1) | AP2013007266A0 (da) |
| AR (1) | AR086631A1 (da) |
| AU (1) | AU2012264765B2 (da) |
| BR (1) | BR112013030995B1 (da) |
| CA (1) | CA2837736C (da) |
| CL (1) | CL2013003459A1 (da) |
| CO (1) | CO6852025A2 (da) |
| CR (1) | CR20130632A (da) |
| CU (1) | CU20130163A7 (da) |
| CY (1) | CY1117660T1 (da) |
| DK (1) | DK2714740T3 (da) |
| DO (1) | DOP2013000285A (da) |
| EA (1) | EA029316B1 (da) |
| EC (1) | ECSP13013063A (da) |
| ES (1) | ES2572215T3 (da) |
| HK (1) | HK1195081A1 (da) |
| HR (1) | HRP20160506T1 (da) |
| HU (1) | HUE028775T2 (da) |
| IL (1) | IL229504B (da) |
| MA (1) | MA35237B1 (da) |
| ME (1) | ME02659B (da) |
| MX (1) | MX343683B (da) |
| PE (1) | PE20141158A1 (da) |
| PL (1) | PL2714740T3 (da) |
| RS (1) | RS54727B1 (da) |
| SG (1) | SG195060A1 (da) |
| SI (1) | SI2714740T1 (da) |
| TN (1) | TN2013000501A1 (da) |
| TW (1) | TWI548649B (da) |
| UY (1) | UY34116A (da) |
| WO (1) | WO2012163932A1 (da) |
| ZA (1) | ZA201309683B (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140135233A (ko) | 2012-03-14 | 2014-11-25 | 리제너론 파마슈티칼스 인코포레이티드 | 다중특이성 항원-결합 분자 및 그것의 용도 |
| LT2935331T (lt) | 2012-12-24 | 2018-06-25 | Abbvie Inc. | Prolaktino receptorių surišantys baltymai ir jų panaudojimas |
| TWI641620B (zh) * | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| MX2017017117A (es) | 2015-07-06 | 2018-03-06 | Regeneron Pharma | Moleculas multiespecificas de union a antigenos y usos de estas. |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| EP3548514A1 (en) | 2016-11-29 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| JP2020527552A (ja) | 2017-07-10 | 2020-09-10 | バイエル・ファルマ・アクティエンゲゼルシャフト | 男性型脱毛症および女性型脱毛症用のプロラクチン受容体抗体 |
| ES2973864T3 (es) * | 2017-08-10 | 2024-06-24 | Grifols Diagnostic Solutions Inc | Composiciones, métodos y/o kits que comprenden un dominio extracelular de CD38 recombinante humano |
| MX2020008274A (es) | 2018-02-07 | 2020-11-11 | Regeneron Pharma | Metodos y composiciones para la administracion de proteinas terapeuticas. |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CN116655791B (zh) * | 2023-05-06 | 2023-11-07 | 浙江触奇生物科技有限公司 | 一种抗泌乳素受体的纳米抗体、重组载体、重组菌和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| WO2003008583A2 (en) | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
| US7705120B2 (en) | 2001-06-21 | 2010-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| EP1325930A1 (en) * | 2002-01-08 | 2003-07-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mammal prolactin variants |
| AU2006235258A1 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes |
| US7422899B2 (en) | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| CA2661023C (en) | 2006-08-18 | 2017-08-15 | Novartis Ag | Prlr-specific antibody and uses thereof |
| EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
-
2011
- 2011-06-03 EP EP11168644A patent/EP2530089A1/en not_active Withdrawn
-
2012
- 2012-05-31 SI SI201230553A patent/SI2714740T1/sl unknown
- 2012-05-31 AU AU2012264765A patent/AU2012264765B2/en active Active
- 2012-05-31 EP EP12729030.2A patent/EP2714740B1/en active Active
- 2012-05-31 EA EA201301356A patent/EA029316B1/ru not_active IP Right Cessation
- 2012-05-31 AP AP2013007266A patent/AP2013007266A0/xx unknown
- 2012-05-31 BR BR112013030995-4A patent/BR112013030995B1/pt active IP Right Grant
- 2012-05-31 CA CA2837736A patent/CA2837736C/en active Active
- 2012-05-31 MX MX2013014174A patent/MX343683B/es active IP Right Grant
- 2012-05-31 CN CN201280038107.4A patent/CN103764679B/zh active Active
- 2012-05-31 DK DK12729030.2T patent/DK2714740T3/da active
- 2012-05-31 JP JP2014513160A patent/JP5859641B2/ja active Active
- 2012-05-31 KR KR1020137034848A patent/KR101920521B1/ko active IP Right Grant
- 2012-05-31 US US14/123,517 patent/US9353186B2/en active Active
- 2012-05-31 ES ES12729030T patent/ES2572215T3/es active Active
- 2012-05-31 HU HUE12729030A patent/HUE028775T2/en unknown
- 2012-05-31 PL PL12729030T patent/PL2714740T3/pl unknown
- 2012-05-31 SG SG2013085816A patent/SG195060A1/en unknown
- 2012-05-31 WO PCT/EP2012/060078 patent/WO2012163932A1/en active Application Filing
- 2012-05-31 RS RS20160322A patent/RS54727B1/sr unknown
- 2012-05-31 PE PE2013002749A patent/PE20141158A1/es active IP Right Grant
- 2012-05-31 ME MEP-2016-91A patent/ME02659B/me unknown
- 2012-06-01 TW TW101119849A patent/TWI548649B/zh active
- 2012-06-01 AR ARP120101933A patent/AR086631A1/es active Pending
- 2012-06-01 UY UY0001034116A patent/UY34116A/es not_active Application Discontinuation
-
2013
- 2013-11-19 IL IL229504A patent/IL229504B/en active IP Right Grant
- 2013-12-02 MA MA36513A patent/MA35237B1/fr unknown
- 2013-12-02 TN TNP2013000501A patent/TN2013000501A1/fr unknown
- 2013-12-03 DO DO2013000285A patent/DOP2013000285A/es unknown
- 2013-12-03 CR CR20130632A patent/CR20130632A/es unknown
- 2013-12-03 CU CU2013000163A patent/CU20130163A7/es unknown
- 2013-12-03 CO CO13283823A patent/CO6852025A2/es not_active Application Discontinuation
- 2013-12-03 EC ECSP13013063 patent/ECSP13013063A/es unknown
- 2013-12-03 CL CL2013003459A patent/CL2013003459A1/es unknown
- 2013-12-20 ZA ZA2013/09683A patent/ZA201309683B/en unknown
-
2014
- 2014-08-18 HK HK14108441.2A patent/HK1195081A1/zh unknown
-
2016
- 2016-04-28 US US15/140,629 patent/US9777063B2/en active Active
- 2016-05-12 HR HRP20160506TT patent/HRP20160506T1/hr unknown
- 2016-06-17 CY CY20161100549T patent/CY1117660T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2714740T3 (da) | Neutraliserende prolactinreceptor-antistof mat3 og terapeutisk anvendelse deraf | |
| US20200197497A1 (en) | Peptidic chimeric antigen receptor t cell switches and uses thereof | |
| US10800828B2 (en) | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer | |
| HRP20170016T1 (hr) | Neutralizirajuća antitijela prolaktin receptora i njihova terapeutska uporaba | |
| AU2011292197B2 (en) | Antibodies that bind myostatin, compositions and methods | |
| HRP20200652T1 (hr) | Ljudska antitijela na fel d1 i metode njihove primjene | |
| HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
| HRP20171653T1 (hr) | Vezna sredstva koja služe ciljano protiv b7-h1 | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| NZ600758A (en) | Antibodies to human programmed death receptor pd-1 | |
| JP2015534577A5 (da) | ||
| JP2015534578A5 (da) | ||
| HRP20192140T1 (hr) | Režimi doziranja anti-folr1 imunokonjugata | |
| RU2018111205A (ru) | Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты | |
| HRP20211453T1 (hr) | Liječenje amd uporabom aav sflt-1 | |
| KR20150093744A (ko) | Bcma 항원 결합 단백질 | |
| JP2012522802A5 (da) | ||
| JP2013135695A5 (da) | ||
| EP1495123A1 (en) | Erbb3 based methods and compositions for treating neoplasms | |
| CN103282054A (zh) | 抗dig抗体和与肽缀合的地高辛配基的复合物的药物组合物 | |
| UA102867C2 (uk) | Антитіла до cxcr4 та їх застосування у лікуванні раку | |
| Liu et al. | Durable remission achieved from Bcma-directed CAR-T therapy against relapsed or refractory multiple myeloma | |
| JP2013531993A5 (da) | ||
| JP2013531991A5 (da) | ||
| EP3999113A1 (en) | Anti-pd-l1 antibodies |